Nanjing Bioheng Biotech Co., Ltd.
Clinical trials sponsored by Nanjing Bioheng Biotech Co., Ltd., explained in plain language.
-
Experimental cell therapy targets Hard-to-Treat autoimmune diseases
Disease control TerminatedThis early-stage study is testing the safety and initial effects of a new cell therapy called RD06-04 for people with active, severe autoimmune diseases. The therapy involves modifying a patient's own immune cells (CAR-T cells) to target and remove certain harmful immune cells. T…
Phase: EARLY_PHASE1 • Sponsor: Nanjing Bioheng Biotech Co., Ltd. • Aim: Disease control
Last updated Apr 02, 2026 05:26 UTC
-
Scientists test 'Living Drug' to reset immune system in 8 serious diseases
Disease control TerminatedThis early-phase study aimed to test a new type of cell therapy for people with serious autoimmune diseases like lupus, multiple sclerosis, and myasthenia gravis. The therapy, called CAR-T, involves modifying a patient's own immune cells to target and remove the cells causing the…
Phase: EARLY_PHASE1 • Sponsor: Nanjing Bioheng Biotech Co., Ltd. • Aim: Disease control
Last updated Mar 27, 2026 12:39 UTC